The Frye-Halloran Symposium is an annual event that aims to facilitate the transition of promising innovations from the laboratory to the care of the patient. Noteworthy past symposia have included the introduction of micro dialysis for real-time in situ measurement of activated drugs, the identification of novel MRI signal changes as markers of the affect of angiogenesis inhibitors, and the development of therapies based upon viral vectors and cell-based immunizations.
The 2010 symposium, taking place on November 11th and 12th, will focus on exploitable signaling pathways and molecular signatures in pediatric brain tumors. Two tumors will be addressed; pediatric medulloblastoma and ependymoma. A group of international experts will discuss the role of molecular subtyping in risk stratification, review the relevant pathways and potential biomarkers in these tumors, and set the rationale for molecularly targeted therapies.
The meeting will be divided into three sessions. Session 1 will focus on the stratification of medulloblastoma by expression analysis, genomic alterations and microRNA profiling and how these molecular signatures can inform risk adjusted therapy. Session 2 will explore the role of the sonic hedgehog and placental growth factor signaling pathways in tumor progression and their potential as therapeutic targets. Session 3 will address the practical issues associated with transitioning these promising molecular strategies into active pediatric cooperative group trials.
We envision the meeting to be of interest to adult and pediatric neuro-oncologists, radiation oncologists, members of academic cooperative groups and those in the field of drug discovery.
The symposium is tuition free and open to all interested parties.